Akorn, Inc., a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics. Its primary products include Akten, a topical ocular anesthetic gel; AzaSite, an antibiotic used to treat bacterial conjunctivitis; Cosopt, Cosopt PF, Betimol, and Zioptan, which are used in the treatment of glaucoma; and Xopenex inhalation solution used in the treatment or prevention of bronchospasm. The Consumer Health segment manufactures and markets OTC products for the treatment of dry eye under the TheraTears brand. It also markets other OTC consumer health products, including Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products. In addition, this segment offers a portfolio of animal health products, such as Anased and VetaKet veterinary sedatives; Tolazine and Yobine sedative reversing agents; and Butorphic, a pain reliever. The company was founded in 1971 and is headquartered in Lake Forest, Illinois.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:AKRX
Previous Symbol
CUSIP00972810
Phone847-279-6100
Debt
Debt-to-Equity Ratio1.26
Current Ratio3.47
Quick Ratio2.46
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E Ratio-53.46
P/E Growth1.27
Sales & Book Value
Annual Sales$841.04 million
Price / Sales1.04
Cash Flow$0.5434 per share
Price / Cash12.79
Book Value$5.20 per share
Price / Book1.34
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-24,550,000.00
Net Margins-34.69%
Return on Equity-14.97%
Return on Assets-6.21%
Miscellaneous
Employees2,308
Outstanding Shares125,490,000
Market Cap$844.56 million
OptionableOptionable
Akorn (NASDAQ:AKRX) Frequently Asked Questions
What is Akorn's stock symbol?
Akorn trades on the NASDAQ under the ticker symbol "AKRX."
How were Akorn's earnings last quarter?
Akorn, Inc. (NASDAQ:AKRX) issued its earnings results on Thursday, August, 4th. The company reported $0.58 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.55 by $0.03. The business earned $280.70 million during the quarter, compared to the consensus estimate of $272.99 million. Akorn had a negative net margin of 34.69% and a negative return on equity of 14.97%. The firm's revenue for the quarter was up 27.1% compared to the same quarter last year. View Akorn's Earnings History.
What price target have analysts set for AKRX?
6 equities research analysts have issued 12-month price targets for Akorn's stock. Their forecasts range from $6.00 to $34.00. On average, they expect Akorn's share price to reach $14.40 in the next year. This suggests a possible upside of 107.2% from the stock's current price. View Analyst Price Targets for Akorn.
What is the consensus analysts' recommendation for Akorn?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akorn in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Akorn.
Has Akorn been receiving favorable news coverage?
Media coverage about AKRX stock has trended somewhat positive this week, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Akorn earned a news sentiment score of 1.5 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the near future.
Who are some of Akorn's key competitors?
Some companies that are related to Akorn include FibroGen (FGEN), Emergent Biosolutions (EBS), Ligand Pharmaceuticals (LGND), Array Biopharma (ARRY), Evotec (EVTCY), Intercept Pharmaceuticals (ICPT), Endo International (ENDP), Madrigal Pharmaceuticals (MDGL), Mallinckrodt (MNK), Blueprint Medicines (BPMC), Ascendis Pharma A/S (ASND), Ultragenyx Pharmaceutical (RARE), ACADIA Pharmaceuticals (ACAD), Allakos (ALLK) and Supernus Pharmaceuticals (SUPN).
Who are Akorn's key executives?
Akorn's management team includes the folowing people:
- Mr. Rajat Rai, Chief Exec. Officer (Age 51)
- Mr. Duane A. Portwood, Exec. VP & CFO (Age 52)
- Dr. Bruce Kutinsky, Chief Operating Officer (Age 52)
- Mr. Joseph Bonaccorsi, Exec. VP, Gen. Counsel & Sec. (Age 53)
- Mr. Jonathan Kafer, Exec. VP of Sales & Marketing (Age 55)
Who are Akorn's major shareholders?
Akorn's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.71%), BlueMountain Capital Management LLC (1.20%), Bank of New York Mellon Corp (1.19%), Dimensional Fund Advisors LP (1.19%), Renaissance Technologies LLC (1.18%) and Deutsche Bank AG (0.74%). Company insiders that own Akorn stock include Brian Tambi, Bruce Kutinsky and John N Kapoor. View Institutional Ownership Trends for Akorn.
Which institutional investors are selling Akorn stock?
AKRX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Stonehill Capital Management LLC, Alpine Associates Management Inc., GABELLI & Co INVESTMENT ADVISERS INC., Nexthera Capital LP, Gabelli Funds LLC, Highbridge Capital Management LLC and Wells Fargo & Company MN. Company insiders that have sold Akorn company stock in the last year include Brian Tambi and John N Kapoor. View Insider Buying and Selling for Akorn.
Which institutional investors are buying Akorn stock?
AKRX stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, BlueMountain Capital Management LLC, Deutsche Bank AG, AQR Capital Management LLC, GSA Capital Partners LLP, Engineers Gate Manager LP, Dimensional Fund Advisors LP and Serengeti Asset Management LP. View Insider Buying and Selling for Akorn.
How do I buy shares of Akorn?
Shares of AKRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Akorn's stock price today?
One share of AKRX stock can currently be purchased for approximately $6.95.
How big of a company is Akorn?
Akorn has a market capitalization of $844.56 million and generates $841.04 million in revenue each year. Akorn employs 2,308 workers across the globe.
What is Akorn's official website?
How can I contact Akorn?
Akorn's mailing address is 1925 WEST FIELD COURT SUITE 300, LAKE FOREST IL, 60045. The company can be reached via phone at 847-279-6100 or via email at [email protected]
MarketBeat Community Rating for Akorn (NASDAQ AKRX)
MarketBeat's community ratings are surveys of what our community members think about Akorn and other stocks. Vote "Outperform" if you believe AKRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
